Sartorius Stedim Biotech's half-year performance in 2026

Sartorius Stedim Biotech announces strong performance for the first half of 2026. The company achieved revenue of €1,527 million, representing a 6.4% increase at constant exchange rates. Current EBITDA amounted to €479 million with a margin of 31.4%, while net income reached €181 million.

Growth was primarily driven by consumables, although equipment showed a slight recovery. Results were impacted by US tariff refunds. All regions showed positive growth, notably Asia/Pacific at 12.5%.

Management remains optimistic for 2026, forecasting revenue growth of between 6% and 10% despite geopolitical uncertainties. Investments have reached €142 million, bringing the capital expenditure to revenue ratio to 9.3%.